NICE says yes to Hycamtin for small-cell lung cancer
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence, is to publish on Wednesday final guidance recommending GlaxoSmithKline's Hycamtin (topotecan) for treating NHS patients in England and Wales with small-cell lung cancer.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.